News and Announcements
YPB Group Strengthens Team with CFO Appointment
- Published July 26, 2016 10:16AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
25th July 2016, ASX Announcement
YPB Group Limited (ASX: YPB) is pleased to announce the appointment of Jason York as Chief Finance Officer (CFO) of the company, effective immediately.
Jason joins us from ConvaTec (a US$1.7b revenue multinational medical technology company) where he was the Vice President of Finance for the Asia Pacific region. Jason is a senior finance executive who has a proven track record in developing high performing finance functions in multinational corporations across various geographies. Jason has strong commercial and financial experience having worked both locally and internationally in his 20-year career.
Jason holds a degree in Economics & Accounting from the University of Canterbury and is a member of the Institute of Chartered Accountants of Australia and New Zealand.
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
